Phase 1c Single Arm Study of Thioredoxin Reductase Inhibitor Ethaselen, for the Treatment of Thioredoxin Reductase High Expressed Advanced Non-small Cell Lung Cancers Who Have Received More Than Two Lines Standard Treatment.

Thioredoxin reductase plays an critical role in lung cancer patients, in vitro study showed that, ethaselen, specific inhibitor of thioredoxin reductase, could inhibit lung cancer cell growth and induce apoptosis. In China, phase 1 clinical trials of ethaselen showed that 1200 mg dose ethaselen could be well tolerated, in pre-clinical study we found that, approximately 50% non-small cell lung cancers harbored high thioredoxin reductase expression(IHC result ++ or +++), phase 1a/b of ethaselen had finished in 2008, the result showed that 1200mg ethaselen per day was safety and tolerated by Chinese malignant tumor patients.In pre-clinical research, our group found that, elevated of thioredoxin reductase activity was associated with the expression of thioredoxin reductase tested by immunohistochemistry, which means high expression of this enzyme may be a favourite predicted factor of ethaselen, the specific inhibitor of thioredoxin reductase.

开始日期2014-06-01

申办/合作机构

湖南省肿瘤医院

100 项与乙烷硒啉相关的临床结果

登录后查看更多信息

100 项与乙烷硒啉相关的转化医学

登录后查看更多信息

100 项与乙烷硒啉相关的专利（医药）

登录后查看更多信息

1,791

项与乙烷硒啉相关的文献（医药）

2024-10-01·Journal of Applied Animal Welfare Science

Hormonal-Induced Cervical Relaxation During Diestrus in Ewes: Cervical Transposing Feasibility and Use of hCG for Rescuing Disrupted Luteal Function

Article

作者: Ferreira Fonseca, Jeferson ; Vergani, Gabriel Brun ; Arrais, Aline Matos ; Garcia, Alexandre Rossetto ; Bastos, Rosemary ; Schinaider Do Amaral Pereira, Verônica ; Rios Coelho Alves, Bruna ; Oliveira, Maria Emilia Franco ; Roberto Bourg Melo, Marco ; Novita Esteves, Sergio

Cervical relaxation (CR) was performed in ewes during diestrus, to prospect a feasible protocol for non-surgical embryo transfer (NSET). In Trial 1, naturally mated ewes (n=13) received CR protocols with estradiol benzoate (EB, 1 mg on D6) and oxytocin (OT, 50 IU on D7) only (G-EB+OT) or associated with human chorionic gonadotropin (hCG, 300 IU on D7, G-EB+OT+hCG) and were compared to non-hormonally treated (G-control) ewes. Estradiol concentration increased (P<0.05) from D6 to D7 in G-EB+OT and G-EB+OT+hCG, then decreased (P<0.05) on D8. The G-EB+OT had reduced (P<0.05) progesterone on D8, and 0% (0/5) pregnancy, while G-control had 100% (3/3) conception rate. The treatment with hCG mitigated the progesterone drop on D8 and resulted in 50% (2/4) conception rate. In Trial 2, cervical transposing success after treatment with EB, OT, and hCG on D6 and D7 was assessed in nulliparous (n=25) and multiparous (n=30) ewes. The EB+OT+hCG protocol allowed efficient cervical transposition (~78% of cervical transposition success into ~5 min) in nulliparous and multiparous females and did not alter total and blood perfusion areas of corpora lutea (CL). The use of EB+OT+hCG was efficient to ensure effective cervical transposing in nulliparous and multiparous ewes, with no apparent deleterious effect on CL function, and may contribute to animal welfare, allowing a less invasive NSET procedure.

2024-07-17·mBio

Edeine B ₁ produced by Brevibacillus brevis reduces the virulence of a plant pathogenic fungus by inhibiting mitochondrial respiration

Article

作者: Lee, Joo-Youn ; Kim, Bomin ; Kim, Yeong Seok ; Choi, Gyung Ja ; Son, Hokyoung ; Han, Jae Woo ; Kim, Hun ; Nguyen, Minh Van ; Park, Jiyeun ; Jeon, Junhyun

ABSTRACT Plant pathogenic fungi cause serious diseases, which result in the loss of crop yields and reduce the quality of crops worldwide. To counteract the escalating risks of chemical fungicides, interest in biological control agents to manage plant diseases has significantly increased. In this study, we comprehensively screened microbial culture filtrates using a yeast screening system to find microbes exhibiting respiratory inhibition activity. Consequently, we found a soil-borne microbe Brevibacillus brevis HK544 strain exhibiting a respiration inhibitory activity and identified edeine B 1 (EB 1 ) from the culture filtrate of HK544 as the active compound of the respiration inhibition activity. Furthermore, against a plant pathogenic fungus Fusarium graminearum , our results showed that EB 1 has effects on multiple aspects of respiration with the downregulation of most of the mitochondrial-related genes based on transcriptome analysis, differential EB 1 -sensitivity from targeted mutagenesis, and the synergistic effects of EB 1 with electron transport chain complex inhibitors. With the promising plant disease control efficacy of B. brevis HK544 producing EB 1 , our results suggest that B. brevis HK544 has potential as a biocontrol agent for Fusarium head blight. IMPORTANCE As a necrotrophic fungus, Fusarium graminearum is a highly destructive pathogen causing severe diseases in cereal crops and mycotoxin contamination in grains. Although chemical control is considered the primary approach to control plant disease caused by F. graminearum , fungicide-resistant strains have been detected in the field after long-term continuous application of fungicides. Moreover, applying chemical fungicides that trigger mycotoxin biosynthesis is a great concern for many researchers. Biocontrol of Fusarium head blight (FHB) by biological control agents (BCAs) represents an alternative approach and could be used as part of the integrated management of FHB and mycotoxin production. The most extensive studies on bacterial BCAs-fungal communications in agroecosystems have focused on antibiosis. Although many BCAs in agricultural ecology have already been used for fungal disease control, the molecular mechanisms of antibiotics produced by BCAs remain to be elucidated. Here, we found a potential BCA ( Brevibacillus brevis HK544) with a strong antifungal activity based on the respiration inhibition activity with its active compound edeine B 1 (EB 1 ). Furthermore, our results showed that EB 1 secreted by HK544 suppresses the expression of the mitochondria-related genes of F. graminearum , subsequently suppressing fungal development and the virulence of F. graminearum . In addition, EB 1 exhibited a synergism with complex I inhibitors such as rotenone and fenazaquin. Our work extends our understanding of how B. brevis HK544 exhibits antifungal activity and suggests that the B. brevis HK544 strain could be a valuable source for developing new crop protectants to control F. graminearum .

2024-07-01·Journal of Dairy Science

Comparison of gonadotropin-releasing hormone and estradiol benzoate plus gonadotropin-releasing hormone to initiate a progesterone-based timed artificial insemination resynchronization protocol in lactating dairy cows

Article

作者: Alves, Rodrigo L O R ; Wiltbank, Milo C ; Motta, Jessica C L ; Sartori, Roberto ; E Silva, Lucas O ; Gonzales, Bruno ; Consentini, Carlos E C ; Abadia, Tattiany ; Melo, Leonardo F

The present study compared 2 strategies to initiate a progesterone (P4)-based timed artificial insemination (TAI) protocol for lactating dairy cows: only GnRH or estradiol benzoate (EB) plus GnRH (EB+GnRH). Lactating Holstein cows (n = 487; 184 primiparous and 303 multiparous) from 2 commercial dairy herds were used for their second or greater services postpartum. Each week, cows that were nonpregnant at the pregnancy diagnosis 32 d after a previous AI were randomly assigned to 1 of 2 experimental groups that differed only in the strategy to initiate (d 0) the TAI protocol. On d 0, every cow received a 2.0-g P4 implant; in the EB+GnRH group, cows were treated with 2.0 mg i.m. of EB and 16.8 µg i.m. of the GnRH analog buserelin acetate, whereas in the GnRH group, cows received only 16.8 µg i.m. of GnRH. On d 7 after the initial treatment, 0.530 mg i.m. of cloprostenol sodium (PGF) was administered in all cows, followed by a second dose on d 8, concomitant with 1.0 mg i.m. of estradiol cypionate and P4 implant withdrawal. The TAI was performed on d 10 (48 h after P4 device withdrawal) in both experimental groups. Only conventional Holstein semen was used throughout the study. The percentage of cows with corpus luteum (CL) on d 0 (73%) and overall ovulation rate after d 0 (54%) did not differ between groups. The CL regression between d 0 and the first PGF treatment was greater in the EB+GnRH group than the GnRH group (42% vs. 31%). Consequently, the proportion of cows with CL at PGF was greater when only GnRH was used on d 0 compared with EB+GnRH (86% vs. 82%), and the mean number of CL at PGF was greater (1.23 vs. 1.11). The expression of estrus near TAI was greater in GnRH group (84% vs. 77%), and cows showing estrus had greater (44% vs. 10%) pregnancy per AI (P/AI) on d 32 for both treatments. We found no effect of the presence of CL on d 0 or at PGF, nor of ovulation after d 0 or CL regression between d 0 and d 7 on fertility. However, fertility was critically impaired when cows did not have CL at both times, d 0 and at PGF treatment. We did not observe any interaction between treatment and other variables, and the P/AI was similar in cows receiving EB+GnRH or only GnRH on d 0 (37.8% vs. 36.6%). In summary, although there was no detectable difference in P/AI between treatments, this study demonstrated potential negative physiological outcomes caused by EB treatment on d 0 (greater incidence of luteolysis after d 0 and fewer cows with CL at PGF treatment). Overall, we found no benefit of adding EB at the initiation of a P4-based TAI protocol on fertility compared with using GnRH alone, despite differences in ovarian dynamics and expression of estrus.

项与乙烷硒啉相关的新闻（医药）

2024-09-06

·米内网

中成药贴膏剂龙头腾飞！奇正手握超20亿独家大品种，羚锐“14连涨”猛攻530亿市场

精彩内容近日，随着A股医药企业上半年业绩披露完毕，奇正藏药、云南白药、羚锐制药3家中成药贴膏剂龙头企业的业绩也浮出水面，均取得亮眼的成绩。其中，奇正藏药贴膏剂收入稳健增长，独家大单品2023年在中国三大终端六大市场的销售额突破20亿元，4款新药在路上；羚锐制药营收实现“14连涨”，净利润连续多年双位数增长，猛攻外用化药530亿市场。中成药贴膏剂百亿市场！奇正、云南白药、羚锐盘踞前三中成药贴膏剂是一种传统经典的中药外用疗法，也是一种现代透皮给药制剂。相比于口服药物，中成药贴膏剂具有无肝脏首过效应、避免胃肠道破坏、毒副作用小、药效持久、使用方便等优点。近年来，人口老龄化加速、慢病年轻化以及消费升级驱动中成药贴膏剂市场的增长。米内网数据显示，2023年中国三大终端六大市场（统计范围详见本文末）中成药贴膏剂销售额超过130亿元，同比增长6.5%，市场规模创近年来新高。近年来中国三大终端六大市场中成药贴膏剂销售情况（单位：万元）来源：米内网格局数据库在一级集团竞争格局中，奇正集团、云南白药、羚锐制药稳居前三，近年来市场份额均在10%以上。其中，奇正集团、羚锐制药近年来持续正增长，2023年奇正集团顶替云南白药，拿下“一哥”宝座。近年来中国三大终端六大市场中成药贴膏剂TOP3集团市场份额情况来源：米内网格局数据库近日，随着A股医药企业2024上半年业绩披露完毕，上述3家中成药贴膏剂龙头企业的业绩也浮出水面，均取得亮眼的成绩。 2024上半年，奇正藏药营业收入10.10亿元（+21.70%），归母净利润3.26亿元（+4.30%）；羚锐制药营业收入19.06亿元（+12.07%），归母净利润4.13亿元（+30.3%）；云南白药营业收入204.55亿元（+0.72%），归母净利润31.89亿元（+12.76%）。奇正藏药：贴膏剂收入稳健增长，4款新药在路上奇正藏药主营业务为藏药的研发、生产及销售，目前拥有以25个独家品种为核心的141个药品批准文号，包括以消痛贴膏（独家）、青鹏软膏、白脉软膏（独家）、铁棒锤止痛膏（独家）等为主的外用系列产品，以及红花如意丸（独家）、如意珍宝片（独家）等口服藏药产品及其他经典中药产品，涵盖骨骼肌肉、神经系统、妇科、儿科、呼吸系统等多个治疗领域。 2024上半年，奇正藏药经营业绩稳步增长，报告期内实现营业收入10.1亿元，同比增长21.7%；归母净利润3.26亿元，同比增长4.3%。从分产品收入看，贴膏剂收入约7.14亿元，同比增长28.37%，占总营收比重超过70%；软膏剂收入约1.33亿元，同比增长20.49%；其他剂型收入约1.52亿元，同比略有下滑...... 贴膏剂为奇正藏药主要收入来源，拥有消痛贴膏、铁棒锤止痛膏、伤湿止痛膏等多个品种。近年来公司的贴膏剂收入持续增加，由2016年的7.4亿元增长至2023年的14.23亿元，2024年有望再创新高。近年来奇正藏药贴膏剂收入情况（单位：亿元）来源：公司公告消痛贴膏为奇正藏药核心产品，已被纳入国家医保乙类、国家基药目录。该产品具有活血化瘀、消肿止痛的功效，用于急慢性扭挫伤、跌打瘀痛、骨质增生、风湿及类风湿疼痛、落枕、肩周炎、腰肌劳损和陈旧性伤痛。针对老龄化趋势，奇正藏药聚焦重点医院，多科室多疾病拓展，深耕骨科，联动康复科、老干科、疼痛科及全科等重点科室，不断增加消痛贴膏在等级及基层的医院覆盖，同时做大线上渠道，B2C、O2O渠道销售显著增长。米内网数据显示，近年来消痛贴膏在中国三大终端六大市场的销售额逐年上涨，2023年突破20亿元，同比增长9.4%。在中成药贴膏剂产品排名中，近年来消痛贴膏稳居首位，市场份额由2019年的约14%提升至2023年的约16%。近年来中国三大终端六大市场消痛贴膏销售情况（单位：万元）来源：米内网格局数据库近年来，奇正藏药持续加大研发投入，推进藏药新药研发、经典藏药二次开发、质量标准提升、资源可持续发展等。2023年公司研发投入接近1亿元，同比增长14.86%；2024上半年以9.86%的同比增速继续增长。在研新药中，催汤颗粒在开展III期临床，用于治疗普通感冒及流行性感冒；消痛气雾剂、正乳贴均处于II期临床，分别用于急性腰扭伤/急性软组织损伤、乳腺增长病；化药1.1类新药乙烷硒啉分散片在开展I期临床，用于治疗恶性实体瘤。此外，白脉软膏用于糖尿病周围神经病变的新适应症于近日获批临床。奇正藏药在开展临床的新药来源：米内网中国临床试验数据库羚锐制药：营收“14连涨”，猛攻530亿市场羚锐制药主营业务为中成药及化药制剂的研发、生产和销售，拥有橡胶膏剂、贴剂、片剂、胶囊剂、乳膏剂等10余种剂型百余种产品，涉及骨科、心脑血管、儿科、癌性疼痛等治疗领域，核心产品包括通络祛痛膏（独家）、活血消痛酊（独家）、壮骨麝香止痛膏、培元通脑胶囊（独家）、丹鹿通督片（独家）、参芪降糖胶囊、芬太尼透皮贴剂等。 2024上半年，羚锐制药经营业绩稳步增长，报告期内实现营业收入19.06亿元，同比增长12.07%；归母净利润4.13亿元，同比增长30.3%。尽管公司半年报未披露分产品收入情况，但其贴剂产品2023年收入20.5亿元，占总营收比例高达61.83%。近年来，羚锐制药表现可圈可点，2011年至2024上半年营业收入实现“14连涨”；2018年至2024上半年，公司归母净利润始终保持两位数增长，这在整个A股医药市场也是比较少见的。近年来羚锐制药业绩情况（单位：亿元）来源：公司公告目前羚锐制药在销的中成药贴膏剂有12种。米内网数据显示，近年来在中国零售药店终端（城市实体药店+网上药店）中成药贴膏剂品牌TOP20中，羚锐制药均有5个品牌上榜，是上榜品牌数最多的企业，其中通络祛痛膏稳居第二。通络祛痛膏为国家医保乙类、国家基药品种，具有活血通络、散寒除湿、消肿止痛等功效，用于腰部、膝部骨性关节炎属瘀血停滞，寒湿阻络证。近年来，该产品在中国三大终端六大市场的销售额逐年上涨，2023年突破10亿元，同比增长28.94%。近年来中国三大终端六大市场通络祛痛膏销售情况（单位：万元）来源：米内网格局数据库为了向更多元、更成熟的制药企业迈进，羚锐制药也在积极布局外用化药制剂、口服制剂等。其中，盐酸洛美沙星乳膏、芬太尼透皮贴剂、吲哚美辛贴片等产品陆续上市，不断丰富公司产品种类，开拓新增量。此外，公司的莫匹罗星软膏以仿制4类报产在审，氟比洛芬凝胶贴膏以仿制4类报临床且在审，盐酸多奈哌齐透皮贴片、格拉司琼透皮贴片等处于I期临床。米内网数据显示，近年来中国三大终端六大市场外用化药（不含生物药）销售额逐年上涨，2023年超过530亿元，同比增长13.81%。从细分剂型看，软膏剂、眼用制剂、贴膏剂依次位列前三。近年来中国三大终端六大市场外用化药（不含生物药）销售情况（单位：万元）来源：米内网格局数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

财报

2024-03-29

·PRNewswire

Journal of Pharmaceutical Analysis (JPA) Studies Find Promising Drug Candidates

Researchers investigate the intricacies of various cellular processes and pathologies and identify compounds with untapped therapeutic potential XI'AN, China, March 29, 2024 /PRNewswire/ -- Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features three articles in which candidate compounds for treating complex disorders were successfully identified, alongside their detailed mechanisms of action. Continue Reading Recent JPA studies identify, through detailed analyses of molecular mechanisms and cellular processes, three potential drug candidates for three different pathologies. The first study investigated the use of metformin (Met), a drug used to manage type II diabetes, for treating benign prostate hyperplasia (BPH). The article was published in Volume 14, Issue 1 of the journal in January 2024. The researchers first sought to shed light on how and which dysregulated sex steroid hormone-related pathways shape the pathological characteristics of BPH, and whether Met can restore these pathways. Through retrospective analysis of data from BPH patients and clinical assessment of serum and tissue samples, the researchers identified dihydrotestosterone (DHT) as a major contributor to BPH among dysregulated sex hormones. DHT promotes prostate cell proliferation by upregulating androgen receptors and forming YAP1-TEAD4 heterodimers. In vivo experiments showed that Met treatment restored sex hormone homeostasis and inhibited DHT-induced cell proliferation. "Our study provided strong evidence that Met might be a promising clinical therapeutic approach for the treatment of BPH," remark corresponding authors Prof. Qian Lu and Prof. Xiaoxing Yin. In the second study, scientists explored the role of epimedin B (EB), the main flavonoid in the Chinese herb Epimedium brevicornum Maxim., in melanogenesis. They expanded on previous findings showing EB's ability to induce melanogenesis and activate tyrosinase family of proteins (TYRs). Through comprehensive in vitro and in vivo experiments on human and animal cells, they uncovered how EB modulated TYRs, increased melanosome numbers, promoted maturation, and aided depigmentation and repigmentation. "Our data reveals that EB can stimulate the pigmentation function of TYRs, which might provide a novel rational strategy for hypopigmentation treatment in the pharmaceutical and cosmetic industries," comments corresponding authors Dr. Yiming Li and Prof. Huali Wu. Finally, in the third study, researchers investigated ferroptosis, a type of programmed cell death, and its role in nerve regeneration after peripheral nerve injury (PNI). They found that oxidative stress at the injury site not only triggered both apoptosis and ferroptosis in nearby neurons by increasing intracellular iron via the degradation of ferroportin by UBA52. Using the Drug Signatures Database, they identified hydralazine (HYD), a potent arterial vasodilator, as a potential UBA52 disruptor. Early HYD administration after PNI in vivo expedited axon regeneration and motor function recovery, partly by suppressing ferroptosis. "The potential clinical implementation of HYD may lead to a reduction in the prevalence of individuals with mild symptoms of nerve damage, consequently mitigating the societal burden," conclude corresponding authors Dr. Bing Xia, Prof. Zhuojing Luo, and Dr. Jinghui Huang. Further studies will hopefully clarify the intricate connections among cellular processes, diseases, and potential drugs, paving the way for precise and efficient therapies. Reference Titles of original papers Metformin: A promising clinSical therapeutical approach for BPH treatment via inhibiting dysregulated steroid hormones-induced prostatic epithelial cells proliferation Epimedin B exhibits pigmentation by increasing tyrosinase family proteins expression, activity, and stability Hydralazine represses Fpn ubiquitination to rescue injured neurons via competitive binding to UBA52 Journal: Journal of Pharmaceutical Analysis DOI 1. 2. 3. Media contact Mengjie Wang [email protected] +86-(0)29-88960092 SOURCE Journal of Pharmaceutical Analysis (JPA)

2023-08-05

·生物制品圈

Moderna2023Q2财报：净亏损14亿美元，未来3年预计推出5款呼吸道疫苗

8月3日，Moderna公布了2023年第二季度财务业绩。2023年上半年，公司总营收22.06亿美元；其中Q2季度收入3.44亿美元，净亏损14亿美元，每股亏损3.62美元，而2022年同期收入为47.49亿美元，收入锐减的主要原因是新冠肺炎疫苗的销量减少。这是Moderna自2020年底新冠疫苗获批以来，首次出现的季度亏损。PS：在【药时空】公众号后台回复关键词“M2023Q2”，即可获取Moderna2023Q2业绩报告资料！尽管如此，Moderna首席执行官Stéphane Bancel仍表示：“鉴于Covid的季节性，第二季度的销售额达到了目标”，且其还上调了今年新冠疫苗销售额预期，根据美国的疫苗接种率，公司预计2023年新冠疫苗销售额将达到60-80亿美元，高于此前至少50亿美元的预测。截至目前，公司共有6个临床3期管线，有7个临床2期管线，47个开发项目。其中3期管线中有4个是传染病疫苗，包括一款RSV疫苗已在美国递交滚动上市申请，在欧洲、澳大利亚等地区递交了正式上市申请；与默沙东合作的肿瘤新抗原mRNA疫苗也已经启动了针对黑色素瘤的三期临床。在呼吸道感染疫苗方面，除新冠疫苗和RSV疫苗外，重点管线还有流感疫苗，包括多款新一代流感疫苗和流感大流行疫苗，另外其还布局了一些组合疫苗。可见，该领域是Moderna布局的重点。在潜在疫苗方面，包括CMV、EBV、HIV等；在新兴疫苗方面，包括寨卡病毒疫苗、莱姆病疫苗等。在未来3年（2024-2026年），Moderna准备推出一系列新产品：如RSV疫苗、季节性流感疫苗、联合疫苗、下一代新冠疫苗、下一代流感疫苗；公司的第一支潜伏性病毒疫苗巨细胞病毒（CMV）疫苗等。在研发费用方面，Moderna加大了投入力度。2023Q2的研发费用比2022年同期增长了62%，达11亿美元。支出增长主要是由于临床试验相关费用的增加，包括RSV、季节性流感和CMV项目。另外，由于支持研究和开发工作的员工人数的增加，相关的人力成本也有所增加。Moderna预计2023年全年公司的研发费用将达到45亿美元。附：Moderna的在研管线&预计在2023年的管线里程碑参考资料：Moderna2023Q2业绩报告资料相关阅读：（1）辉瑞、默沙东2023Q2财报发布，这4款潜力疫苗产品值得期待！（附报告下载）（2）赛诺菲、GSK 2023Q2财报发布，这5款疫苗产品值得关注！（附最新管线）

财报疫苗临床3期信使RNA

100 项与乙烷硒啉相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15051

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血液肿瘤	临床2期	中国	北京大学	-
血液肿瘤	临床2期	中国	凯熙医药（武汉）股份有限公司	-
非小细胞肺癌	临床1期	中国	湖南省肿瘤医院	2017-10-16
晚期恶性实体瘤	临床1期	中国	北京大学	2014-08-29
晚期恶性实体瘤	临床1期	中国	西藏奇正藏药股份有限公司	2014-08-29